ASHP therapeutic position statement on optimizing treatment of hypertension

American Journal of Health-System Pharmacy

Volumn 57, Issue 2, 2000, Pages 162-173

  Carter, B L ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Angiotensin converting enzyme inhibitors; Calcium antagonists; Diuretics; Hypertension; Protocols; Sympatholytics agents

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG COST; DRUG INDICATION; HYPERTENSION; LIFESTYLE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

EID: 0034650508     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.2.162     Document Type: Review

References (55)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2414-46.
2. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995; 26:60-9.
3. Healthy people 2000. Washington, DC: U.S. Department of Health and Human Services; 1990.
4. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998; 351:1755-62.
5. Lazarus JM, Bourgoignie IJ, BuckalewVM et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 29:641-50.
6. Appel LJ, Moore TJ, Obarzanek E et al., for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997; 336:1117-24.
7. Welton PK, Appel LJ, Espeland MA et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998; 279:839-46.
8. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45.
9. Staessen JA, Fagard R, Thijs L et al., for the Systolic Hypertension - Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997; 360:757-64.
10. Staessen JA, Thijs L, Fagard RH et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Calcium channel blockade and cardiovascular prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension. 1998; 32:410-6.
11. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64.
12. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC-V recommendations affect prescribing? JAMA. 1997; 278:1745-8.
13. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998; 279: 1813-6.
14. Cutler JA. Calcium-channel blockers for hypertension: uncertainty continues. N Engl J Med. 1998; 338:679-81.
15. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52.
16. Borhani NO, Mercuri M, Borhani P et al. Final outcome results of the Multicenter isradipine Diuretic Atherosclerosis study (MIDAS): a randomized controlled trial. JAMA. 1996; 276:785-91.
17. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603.
18. Tuomilehto J, Rastenyte D, Birkenhäher WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999; 340: 677-84.
19. Pearce KA, Furberg CD, Psaty BM et al. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens. 1998; 11:618-29.
20. Neaton JD, Grimm RH, Prineas RJ et al., for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA. 1993; 270:713-24.
21. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993; 328:914-21.
22. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998; 279:1903-7.
23. Frost PH, Davis BR, Burlando AJ et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 1996; 94:2381-8.
24. Savage PJ, Pressel SL, Curb JD et al. Influence of long-term, low-dose-diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1998; 158: 741-51.
25. Lakshman MR, Reda RJ, Materson BJ et al. Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipids and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999; 159:551-8.
26. Curb JD, Pressel SL, Cutler JA et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996; 276:1886-92.
27. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353:611-6.
28. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 1998; 317:713-9.
29. Shorr RI, Ray WA, Daugherty JR et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997; 278:40-3.
30. Nielsen FS, Rossing P, Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997; 46:1182-8.
31. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998; 317:703-12.
32. Ismail N, Becker B, Strzelczyk P et al. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int. 1999; 55:1-28.
33. Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339:1957-63.
34. Thrift AG, McNeil JJ, Forbes A et al. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Hypertension. 1998; 31:1223-9.
35. Roter DA, Hall JA, Merisca R et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998; 36:1138-61.
36. Manolio TA, Cutler JA, Furberg CD et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155:829-37.
37. National High Blood Pressure Education Program. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993; 153:154-83.
38. Malcolm LA, Kawachi I, Jackson R et al. Is the pharmacologic treatment of mild to moderate hypertension cost effective in stroke prevention? N Z Med J. 1988; 101: 167-71.
39. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens. 1991; 9: 199-208.
40. Fletcher A. Economics of hypertension control: a statement by the World Hypertension League. J Hum Hypertens. 1994; 8:789-95.
41. Hilleman DE, Mohiuddin SM, Lucas BD Jr et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-rnoderate essential diastolic hypertension. Clin Ther. 1994; 16:88-102.
42. Siegel D, Lopez J, Meier J. Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996. Am J Hypertens. 1998; 11:1271-8.
43. Draft HEDIS 2000. Washington, DC: National Center for Quality Assurance; 1999: 25-32.
44. Alsuwaidan S, Malone DC, Billups SJ et al. Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. Am J Health-Syst Pharm. 1998; 55: 68-72.
45. Hawkins DW, Fiedler FP, Douglas HL et al. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm. 1979; 36:1321-5.
46. Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy: clinical pharmacists in outpatient therapy. Arch Intern Med. 1981; 141:1441-4.
47. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control: a four-year analysis of an ambulatory care model. Arch Intern Med. 1984; 144:1159-62.
48. Morse GD, Douglas JB, Upton JH et al. Effect of pharmacist intervention on control of resistant hypertension. Am J Hosp Pharm. 1986; 43:905-9.
49. McGhan WF, Stimmel GL, Hall TG et al. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care. 1983; 21: 435-44.
50. Solomon DK, Portner TS, Bass GE et al. Part 2: clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc. 1998; 38:574-85.
51. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997; 17:140-7.
52. McKenney JM, Slining JM, Henderson HR et al. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973; 48:1104-11.
53. McKenney JM, Brown ED, Necsary R et al. Effect of pharmacist drug monitoring and patient education on hypertensive patients. Contemp Pharm Pract. 1978; 1:50-6.
54. Park JJ, Kelly P, Carter BL et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc. 1996; 36:443-51.
55. Carter BL, Barnette DJ, Chrischilles E et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997; 17:1274-85.